Praxis Precision Medicines (PRAX)
(Real Time Quote from BATS)
$48.59 USD
+0.80 (1.67%)
Updated Aug 6, 2025 03:53 PM ET
After-Market: $48.74 +0.15 (0.31%) 4:12 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PRAX 48.59 +0.80(1.67%)
Will PRAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRAX
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
PRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ensign Group (ENSG) Q4 Earnings and Revenues Beat Estimates
Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
Other News for PRAX
Praxis Precision Medicine (PRAX): HC Wainwright & Co. Raises Price Target | PRAX Stock News
PRAX Price Target Increased by H.C. Wainwright Following Positive Trial Results
Praxis Precision Medicines to Participate in Upcoming Fireside Chat | PRAX Stock News
Praxis Precision price target raised by $10 at H.C. Wainwright, here's why
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ...